Biologics/Immunotherapy News

SAN DIEGO — Patients with multiple food allergies introduced allergens into their diets after using omalizumab, researchers reported at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

SAN DIEGO — A retrospective chart review of patients with allergy who participated in subcutaneous immunotherapy and oral food challenges suggested that these therapies should be expanded, according to a pair of posters presented here.

SAN DIEGO — Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a median of zero after the first month and at 12 months, according to a poster presented here.

SAN DIEGO — Patients with three different food allergies who used omalizumab experienced better outcomes than patients who used multi-food oral immunotherapy, driven by lower rates of adverse events, according to an abstract presented here.

SAN DIEGO — Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food elimination diets during treatment, according to a poster presented here.

Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals of Allergy, Asthma & Immunology.

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert A. Wood, MD, FAAAAI, professor of pediatrics, Johns Hopkins University School of Medicine, told Healio.

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.

Two-thirds of toddlers with peanut allergy who used the VIASKIN Peanut patch from DBV Technologies completed an oral food challenge at 36 months without meeting criteria for stopping, according to a webinar held by the company.

Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.